0000899243-18-018502.txt : 20180627
0000899243-18-018502.hdr.sgml : 20180627
20180627203529
ACCESSION NUMBER: 0000899243-18-018502
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180625
FILED AS OF DATE: 20180627
DATE AS OF CHANGE: 20180627
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shannon John Patrick Jr
CENTRAL INDEX KEY: 0001553595
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38536
FILM NUMBER: 18923019
MAIL ADDRESS:
STREET 1: DURATA THERAPEUTICS, INC.
STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001346302
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203352427
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
BUSINESS PHONE: 512-498-2670
MAIL ADDRESS:
STREET 1: 180 NORTH LASALLE STREET
STREET 2: STE 1800
CITY: CHICAGO
STATE: IL
ZIP: 60601
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-25
0
0001346302
XERIS PHARMACEUTICALS INC
XERS
0001553595
Shannon John Patrick Jr
C/O XERIS PHARMACEUTICALS, INC.
180 N. LASALLE STREET, SUITE 1810
CHICAGO
IL
60601
0
1
0
0
See Remarks
Common Stock
2018-06-25
4
C
0
8983
A
8983
D
Series C Preferred Stock
2018-06-25
4
C
0
16000
D
Common Stock
8983
0
D
Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
Executive Vice President and Chief Operating Officer
/s/ Barry Deutsch, as Attorney-in-Fact
2018-06-26